Methodology

How We Evaluate Every Product

Every product on DermApproved goes through the same evaluation — whether it's a $9 drugstore cleanser or a $300 luxury serum. For each concern a product claims, we answer three questions from its ingredient list and a versioned clinical-evidence table, and read a verdict off a published rule register — words, never a blended number. A deterministic scoring engine sits underneath, and a detailed editorial review grounded in published research sits beside it. Then we turn all of that into recommendations tuned to your skin.

This is the technical companion to How It All Works: that page tells the story of the whole system; this one shows the work — how a verdict is decided, where the evidence behind it comes from, what the engine underneath computes, and how confident we are in each reading — so you can decide for yourself how much weight to give our assessments.

Verdicts

How a Verdict Is Decided

For every product and every concern it claims to help, we answer three questions and read the verdict off a published rule tree — no weighted number, no blend. Does it contain an active with documented standing for this concern? Is it present in a form that can work? Is it likely to be tolerated for this concern? Every verdict on the site names the rule that produced it, and every rule is listed here with its reasoning. A verdict is our assessment of how well a product’s ingredients fit a concern; it is never a claim about what the product treats.

Strong choice

A first-line active — approved, monograph-listed or named in current guidelines — at an effective strength, with no trigger for the concern.

Good choice

A trial-supported active at a working level, or a first-line active below its studied range.

Full protection

Broad-spectrum SPF 30 or higher with an adequate UVA filter (and iron oxides where visible light matters).

Supporting role

Nothing here targets the concern directly, but the product’s job — barrier care, gentle cleansing, photoprotection — is the recognised companion to treating it. Rinse-off products carrying leave-on actives land here too.

Not for this

The actives have been researched for this concern and the evidence does not support the claim.

Not yet assessed

No evidence row yet for the actives on this concern — they are in the research queue, and the backlog is public.

Falls short

A sunscreen without an adequate UVA filter in its ingredient list.

Avoid

The formula carries a known trigger for the concern — fragrance for rosacea, comedogenic esters for acne, fungal triggers for fungal acne — which decides the verdict before any efficacy question.

Unproven

The lead active has early or mechanistic evidence only, or is present below a working level. A reasonable bet, not a recommendation.

Promising

The lead active has trial-level evidence for the concern but no guideline or regulatory standing yet, and is present at a working level. Promising, short of a recommendation — the evidence dots beside it say how much trial evidence there is.

Basic protection

Broad-spectrum SPF 15–29: meets the FDA bar for the early-skin-aging claim, below the SPF 30 dermatologists recommend daily.

The rule register rules 0.5.1 · evidence table ev-2026.09-r228

Rules are evaluated in order; the first that matches decides. The register and its anchor set are editorial decisions, each with a written rationale, and stand pending review by a dermatology advisory panel as a method — no advisor is, or will be, named on a rule or a product.

Sensitivity (tolerability only)

RuleVerdictWhen, and why
F1 Avoid q3 = harsh
Sensitivity has no efficacy claim; the verdict is tolerability.
F2 Good choice q3 = gentle
Gentle = no weighted deduction fired and fit ≥ 90.
F3 Supporting role otherwise
Standard tolerability with a minor weighted leaf.

Concerns

RuleVerdictWhen, and why
R1 Avoid q3 = harsh
Safety outranks praise (MASTER-PLAN §1.7). A condition-weighted trigger (multiplier ≥ 2 in condition-fit-matrix) decides the verdict before any efficacy question.
R2r Good choice q1 = first-line | supported · q2 = adequate | plausible · rinse = true · scalp = false
Rinse-off exceptions (BPO wash, salicylic acid cleanser) deliver a real but smaller effect than the leave-on form; they cap at 'good choice'. Medicated shampoos for scalp concerns are exempt — the shampoo is the treatment form. Editorial decision 2 Sep 2026, pending advisory review.
R2 Strong choice q1 = first-line · q2 = adequate
A regulator- or guideline-recognised first-line active, declared at an effective strength, in a form the claim supports.
R3 Strong choice q1 = first-line · q2 = plausible
Undeclared but plausibly dosed (top-third INCI position, or a potent sub-1% active) — the verdict stands, and the sentence says what disclosure would add. A declared figure below range would have been sub-threshold.
R4 Good choice q1 = first-line · q2 = sub-threshold
Right molecule, weak dose: still a reasonable choice, not the strong one.
R5 Good choice q1 = supported · q2 = adequate | plausible
Trial-supported or guideline-supported active, adequately or plausibly dosed.
R6 Supporting role q1 = first-line | supported | plausible | none | not-assessed · q2 = contact-limited
Contact time cannot deliver a leave-on claim; the product is judged on its job (cleansing without aggravating). Explicit exceptions (BPO wash, SA cleanser, medicated shampoos) never reach this rule because their rows set rinse_off_ok.
R7 Supporting role q1 = supported · q2 = sub-threshold
A supported active under-dosed cannot be recommended for the concern; if the category has a supportive job it may still help alongside treatment.
R8a Supporting role q1 = plausible · q2 = adequate | plausible · supportive = true
A plausible-tier active in a category with a supportive job: the sentence names the active instead of saying nothing targets the concern (the AmLactin / CeraVe SA case for keratosis pilaris, where no guideline and single trials leave the keratolytics at early evidence).
R8 Supporting role q1 = plausible | none | not-assessed · supportive = true
The category's job (barrier care, humectant hydration, gentle cleansing, photoprotection) is the documented supportive role for this concern. This is the honest verdict for a moisturizer on an acne page.
R9p Promising q1 = plausible · q2 = adequate | plausible · supportive = false · strength = moderate | strong
0.5.0: 'Unproven' beside three filled dots read as one question answered twice with opposite words (7,018 rows). The chip measures standing, the dots measure trial volume; where the row carries at least one RCT or a tier-2 source (moderate dots) and the active is present at a working level, the honest word is Promising. Unproven is reserved for plausible-standing rows with limited or weak evidence, or an under-dosed form. Same rank as Unproven — a bet either way; the dots order them.
R9 Unproven q1 = plausible · supportive = false
Plausible-tier actives alone do not earn a recommendation, and 'not for this' would overstate the case against them. 'Unproven' with the evidence dots lets the reader judge the bet (added 0.2.0 after the first shadow run put a 10% niacinamide serum at 'not for this' for hyperpigmentation). 0.5.0: the closing clause reads the other heroes — "nothing else here addresses it" only when every other active has a researched 'none' row; "not yet assessed" when that is the truth. Rows whose dots read moderate or better now reach R9p first.
R10 Not for this q1 = none · supportive = false
Researched and found wanting is a different sentence from unresearched (R11).
R11 Not yet assessed q1 = not-assessed · supportive = false
Not assessed is a state, not a number (MASTER-PLAN §1.6). It can never outrank a researched active, and the backlog is published.
R12 Not for this q2 = neutralised
The 4.8.0 G5 self-neutralising rule, now a verdict rule.

Sunscreens

RuleVerdictWhen, and why
P1 Full protection uva = true · spf_band = 30+ · iron_oxides_needed = false
Photoprotection standing is regulatory (M020 / Annex VI filters; 21 CFR 201.327 attaches the early-skin-aging claim to tested broad-spectrum SPF 15+). SPF 30 is the AAD daily-use bar.
P2 Full protection uva = true · spf_band = 30+ · iron_oxides_needed = true · iron_oxides = true
Melasma needs visible-light attenuation; iron oxides are the documented route.
P3 Basic protection uva = true · spf_band = 30+ · iron_oxides_needed = true · iron_oxides = false
Full UV protection without the visible-light layer melasma needs.
P4 Basic protection uva = true · spf_band = 15-29 | unstated
SPF 15–29 broad-spectrum is protection, not the recommended level; 'falls short' would misstate a regulator-recognised product.
P5 Falls short otherwise
No adequate UVA filter in the ingredient list is the one failure that makes a sunscreen fall short whatever its SPF.

Category job

RuleVerdictWhen, and why
J1 Excellent at the job job_score_min = 85 · job_measured_min = 4
Category job score ≥ 85 over at least four measured features (0.5.1: three binary checks — UVA filter, photostability, tolerability — passed on 95 % of sunscreens and read 'Excellent' for a checklist; with fewer than four measurable features a category caps at Does the job). The concern verdicts carry the judgement; the job line states the function.
J2 Does the job job_score_min = 65
Category job score over the measured features 65–85.
J3 Falls short otherwise
Category job score below 65 over the features that can be measured from the label (5.1.0: unmeasured features no longer enter at a prior; when under half the spec's weight is measurable there is no job verdict). The sentence names the criterion missed, never 'its basics'.

Triggers that make a formula an avoid for a concern are listed per concern in the same register; cautions — a photosensitising active, a strong acid, a single declarable allergen — add a caution line to a verdict and never decide it. A Tier 1 or 2 seal from an expert body (the National Eczema Association, the Canadian Dermatology Association and their peers) outweighs a trigger for the concern the seal covers.

The engine underneath

Two Scores, Built From Evidence

Beneath the verdicts, the engine still computes an Overall Score (0–100) and, for each concern a product addresses, a Condition Grade (A+ to F). Since the verdict cutover neither is shown on a product page or a card — a verdict says what a number cannot, and a number invites a ranking the evidence does not support — but they still drive safety gates, the tolerability question inside every verdict, and the category "job" reading, and both unfold into a citable audit trail. They are computed independently: the Overall answers "how good is this product?", the grade answers "how good is it for this specific job?"

The Overall Score — six factors

Formula quality — 25%

Evidence level of the actives (from our graded clinical-evidence table), their effective dose, and formulation craft — pH, photostability, and antagonism checks from the full INCI list.

Safety & tolerability — 20%

Fragrance, sensitizing preservatives, drying alcohols, and known irritants — judged at the concentration and contact time they actually occur at. The same fragrance is a different proposition in a 30-second cleanser and an eight-hour night cream.

Real-world results — 20%

What genuine reviews report, after de-biasing — verified-purchase weighting, an incentivized-review offset, distribution-shape checks, and shrinkage toward the category baseline so a handful of glowing reviews can't dominate.

Usability & feel — 10%

Texture, finish, white-cast on mineral SPF, pilling, and whether the packaging protects an oxidation-prone active.

Value — 15%

Price per unit against the real category median — earned by the formula, not the jar. Value is never derived from popularity, which would let a fashionable product inflate its own price justification.

Brand trust — 10%

Track record and the depth of a brand's clinical validation, by founding era — not marketing spend.

No factor sits below 10% — anything that can't earn a tenth of the score becomes displayed information instead of a decorative weight. And every fact has exactly one scoring owner: fragrance is priced in safety, texture in usability, price in value. Nothing scores twice under two names.

The Condition Grade

Grade(condition) = FormulaForJob × 0.50 + Fit × 0.30 + Outcomes × 0.20

For a given concern, half the grade is how well the formula is evidenced for that job (itself split across evidence strength, dose adequacy, and formulation craft), a third is how well it fits that skin's tolerance and constraints, and a fifth is what users with that concern actually reported. Grades exist for 26 concerns, and a product is graded separately for each one it addresses — a rich ceramide balm can hold an A for eczema and a D for fungal acne at the same time, because both are true.

Grade boundaries are frozen

The A+-to-F boundaries were calibrated once against the full-catalogue distribution and then locked. A product's grade moves only when its own data moves — never because the field shifted around it. A+ is roughly the top 2% of all grades; A− or better roughly the top 15%.

The Evidence Table

Where the Numbers Come From

Underneath the engine sits a versioned table of ingredient–claim pairs — currently 228 reviewed rows, expanding continuously. Each row is not "niacinamide is good"; it is "niacinamide for post-inflammatory hyperpigmentation", as a separate row from "niacinamide for barrier support", because those claims have different evidence bases. Each row records what the primary literature actually measured — trial design, population, dose, duration, endpoint — and its evidence tier is computed from those findings, never typed in by judgement. Every row carries its sources, its reviewer, and its review date.

Three rules keep the table honest. Claims never transfer: a trial measuring post-inflammatory hyperpigmentation is evidence for PIH, and is never borrowed for melasma — which relapses and defeats treatments that clear PIH easily. Dose matters: a positive result at 4% for 12 weeks is not evidence for a product containing 0.5%. Unknown is a real value: an unverifiable concentration scores neutral and lowers stated confidence — never rounded up (which would credit marketing) and never rounded down (which would punish proprietary formulations for not disclosing).

Every citation on the site is confirmed against the source database before it publishes — the title, journal, and year of the paper at the link must match the reference that cites it. A plausible-looking link to the wrong study is worse than no link, so it's checked by machine, across every product review, ingredient reference, therapy guide, and article.

Outcomes

Reading Reviews Instead of Counting Stars

A 4.7-star average tells you a product pleased people; it can't tell you it failed everyone with rosacea. So the outcomes factor is built from review text, collected from retailer and platform APIs and passed through a fixed extraction model — measured against human coding at κ = 0.851, a level of agreement generally considered strong. It reads what people with a specific concern actually reported, feeds the condition grades with concern-matched outcomes, and flags undisclosed promotional reviews — on some products we've found 36–50% of reviews were seeded placements, invisible in the star average everyone shops by.

Where reviews haven't been collected for a product yet, the grade still exists — it runs on formulation and clinical evidence, and is labelled accordingly rather than padded with a guess.

Hard Gates

What No Score Can Outweigh

Weights price ordinary differences. Six gates handle the things that should disqualify a product no matter how well it scores. A gate can only be entered through its published criteria — never by editorial judgement — and every gate has exit criteria, a review schedule, a disputed state for findings under formal challenge, and a written appeal path.

Recall or contamination

An active recall or a verified contamination finding.

False clinical claims

Marketing that asserts clinical results the evidence contradicts.

Review manipulation

Documented seeding or manipulation of user reviews.

Category integrity

A "sunscreen" without adequate UVA filtration — derived from its own ingredient list.

Self-neutralizing formula

A formulation that inactivates its own hero ingredient.

Expert consensus of inefficacy

A settled expert consensus that the product does nothing.

Evidence Framework

How We Read the Evidence for an Ingredient

Every hero ingredient is graded against a published evidence table, one row per ingredient and concern — azelaic acid for rosacea is a different row from azelaic acid for acne. Each row answers two separate questions, and the product page shows both, because they are not the same claim.

1 · Standing — is it recognised as a treatment for this concern?

Regulator-approved (an FDA-approved or monograph active for this indication) · Named in treatment guidelines · Clinically supported (trial-backed, not guideline-named) · Established mechanism (reference standards such as petrolatum or glycerin, where the effect is physics rather than a trial) · Not established. Standing is what a dermatologist would call the ingredient's role, and it must rest on a document we opened and dated — a regulation, a guideline, a systematic review. It never rests on a person.

2 · Certainty — how much dedicated evidence is behind it?

Well-established (multiple trials or a meta-analysis, replicated) · Promising · Emerging (early human studies) · Limited (small or indirect trials) · Traditional use · Contradicted (evidence of no effect). Certainty is derived by a fixed rule from the row's trial count, replication, consistency and source quality, and is never typed by hand.

Why two answers, not one

Sulfur is monograph-recognised for acne on a thin modern trial base — "regulator-approved, limited certainty" is the honest reading, and collapsing it to one word would either overstate the trials or hide the standing. Zinc oxide has no trial isolating it for photodamage, yet FDA attaches the early-skin-aging claim to tested broad-spectrum sunscreens that contain it. The two answers are kept apart everywhere they appear.

Not yet assessed

An ingredient with no row for a concern is not "weak" — it is unresearched, and the page says so. It cannot carry a grade above the neutral prior, and the queue of ingredients awaiting a row is part of the published methodology rather than a hidden gap.

Where you see this

The Key Ingredients table on every product page shows each hero's standing and certainty for the concern it is graded against, read from the same table the engine scores from. The studies behind any grade are one tap away on the concern card.

Confidence

How Confident We Are in Each Number

A score of 84 backed by 15 years on the market and 50,000 reviews is a different finding than an 84 on a three-month-old launch. So a confidence band sits beside the assessment on the product page, at equal visual rank — it is never absorbed into the number itself. Uncertainty lowers confidence, not the score.

High

The data is substantially complete: an established market history, collected real-world reviews that are reasonably fresh, and well-researched actives. The assessment rests on validation, not projection.

Moderate

Solid formulation data with gaps elsewhere — a thinner review base, an aging collection pass, or undisclosed concentrations scored at neutral. Well-supported, and liable to sharpen as data lands.

Early

A recent launch, or a product whose reviews we haven't collected yet. The assessment runs on formulation analysis and clinical evidence for the ingredients — stated plainly on the page, and revisited as real-world data arrives.

From Numbers to Recommendations

The Same Grades Everywhere You Look

The scores aren't decoration on the product page — they are the ranking machinery for the whole site. Every "best for [concern]" list is ordered by the relevant condition grade with a hard floor at B−, so a list titled "best moisturizer for rosacea" is ranked by the rosacea grade, not by a general number that knows nothing about rosacea. And once you've set up a skin profile, product cards across the site carry letter badges for your concerns — computed by the same engine, from the same table, with the same audit trail behind them.

Editorial

What's in Every Review

Beyond the numbers, every product gets an 800–1,500 word editorial review — a genuine analysis written by someone who understands formulation science, opening with a unique angle rather than the same template. Each one also carries the sections below.

Science Section

200–400 words on the evidence behind the product's key actives — focused on the specific combination and delivery system in that formula, not generic monographs. Every study reference is verified against published databases; if we can't confirm a study, we describe the general evidence base instead of inventing a citation.

Dermatologist Perspective

Clinical context drawn from publicly available dermatologist guidance, written in third person — "dermatologists frequently recommend…" rather than impersonating a specific doctor.

Value Assessment

A frank read on whether the price matches the formula, factoring in brand heritage. We say plainly when a product earns its price and when you're paying for packaging.

Practical Guidance

How and when to apply it, what to expect as a first-time user (purging, tingling, adjustment periods), a sample AM/PM routine, and who should buy versus skip — plus 6–8 concrete pros and 4–6 honest cons.

How We Judge

Hype-Aware, Never Cynical

Not every product earns the attention it gets. We apply friendly skepticism where it's warranted — always assessing the formula on its merits, never punching down.

Celebrity & Influencer Brands

The name on the label got you here — but we focus on what's inside the bottle. We give credit where it's earned, and flag when a price tag reflects fame rather than ingredients.

Hype-Driven Indies

Social media virality is not an ingredient. When a product's main credential is "sold out three times," we look for the substance behind the aesthetic — and say so clearly when it's actually there.

Luxury Pricing

A $90 moisturizer should earn its price in the formula, not the packaging. If the INCI list reads like a $20 product in a heavier jar, we'll tell you — diplomatically, but clearly.

"Clean Beauty" Claims

If a brand markets on fear-based claims like "free from toxins," we address it factually. We never mock people who care about clean products — we help them tell meaningful from marketing.

Where does all this data go once it's scored? The site personalizes itself around your skin — that story, from the skin profile to the full toolkit, is told in How It All Works.

Transparency

We Show Our Work

Everything that goes into an assessment is on the page — and it goes all the way down. The headline grade opens into the factors that produced it; each factor opens into the individual measured facts (which ingredient, at what dose, judged against which claim); each fact opens into the studies themselves, with title, journal, year, and a link to the paper. If we're uncertain, the confidence band says so. You might weigh tolerability more heavily than we do, or care more about evidence strength than value — by exposing the breakdown, we let you apply your own priorities instead of just accepting ours.

And none of it is frozen. As formulas change, new research is published, or collected reviews reveal patterns we missed, the engine re-derives the numbers — every new row in the evidence table sharpens every grade that depends on it, across the whole catalogue at once. The goal isn't to be right the first time every time — it's to be honest, thorough, and continuously improving.

Ready to Find Better Products?

Set up your skin profile and browse products that actually fit your skin.

Start With My Skin